BIT Capital GmbH Takes Position in Kiniksa Pharmaceuticals International, plc $KNSA

BIT Capital GmbH purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 12,800 shares of the company’s stock, valued at approximately $528,000.

Several other hedge funds also recently made changes to their positions in the company. State of Wyoming grew its holdings in shares of Kiniksa Pharmaceuticals International by 66.8% during the fourth quarter. State of Wyoming now owns 13,280 shares of the company’s stock worth $548,000 after buying an additional 5,318 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Kiniksa Pharmaceuticals International by 51.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 829,417 shares of the company’s stock worth $34,213,000 after buying an additional 282,907 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Kiniksa Pharmaceuticals International by 27.3% in the 4th quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after purchasing an additional 178,366 shares in the last quarter. Legato Capital Management LLC boosted its holdings in Kiniksa Pharmaceuticals International by 9.5% in the 4th quarter. Legato Capital Management LLC now owns 63,137 shares of the company’s stock valued at $2,604,000 after purchasing an additional 5,496 shares in the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA opened at $48.42 on Friday. The firm’s 50-day moving average is $50.18 and its 200-day moving average is $45.64. Kiniksa Pharmaceuticals International, plc has a 52-week low of $26.27 and a 52-week high of $59.87. The company has a market cap of $3.73 billion, a price-to-earnings ratio of 53.80 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 EPS. Equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on KNSA shares. Citigroup lifted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, May 6th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Finally, Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $60.86.

Insiders Place Their Bets

In related news, CAO Michael R. Megna sold 6,625 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $309,321.25. Following the sale, the chief accounting officer owned 27,418 shares of the company’s stock, valued at $1,280,146.42. The trade was a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 1,703 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $79,513.07. Following the completion of the sale, the chief operating officer directly owned 12,029 shares in the company, valued at approximately $561,634.01. The trade was a 12.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 653,301 shares of company stock valued at $34,046,073 over the last 90 days. Company insiders own 51.98% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.